{"ticker": {"uuid": "2332dec9-d978-4151-b8c9-0c560fb9cb5f", "symbol": "IRWD", "name": "Ironwood Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Ironwood Pharmaceuticals (IRWD) adds 10M shares to 2019 equity incentive plan", "summary": "Ironwood Pharmaceuticals (IRWD) announced that its stockholders approved an amendment to the 2019 Equity Incentive Plan, adding 10 million shares of Class A common stock for future equity-based compensation. This approval occurred at the 2026 Annual Meeting of Stockholders, where", "url": "https://www.stocktitan.net/sec-filings/IRWD/8-k-ironwood-pharmaceuticals-inc-reports-material-event-b2fcb635b377.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:14:32", "published_display": "18 Jun 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood (IRWD) director Jay Shepard receives 63,481-share restricted stock grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPdzNFZVdwd3lTQUZSQXNTVTNFV2ZHX3U3b0x2VnJBQnRJbzllMDBySjFtVUpnWExPMWNHaHplTHlQTFlqdXU3QnYwUUNHNjRSNFRpdDZyVnhJMWszYllVc2lOLWdlY2paZ3BfRmJsLTc1c05hSk5TUkN6eGZIX0xVQXBnelNidE94Z0lDUm1FdVl2Ti0yNENBSjFfUGZHWUg5VWlUSUhCVTgwdDlyb0NrYm56WHJRWjdXTTVyYm9PNA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T20:47:05+00:00", "published_display": "17 Jun 2026 20:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Catherine Moukheibir receives 63,481 Ironwood (IRWD) restricted shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQSWwzaE1rQ1Q1WHI0MlZNSUZzU2cxbWZHQUZQYWVyYWs4VG5ENmkzRFRYYVJiSG0tTFpGbksxT2tQOTFlRWZWWW1RVnNRb2ZPdF94QWpiOHJZdzVVMTNKbU1iNWhhMnRpYWZrcEhuaVJ6c0RBcVFtUXdGYWZ1R0tJV2oxVHQ4OFFSMG5XUUc1b212ek5mR240SVhNRDdjLUJDY0kxZmhHYVNhOFhLRXVkT3l6YzI2eDcxVExPQmpMQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T20:36:28+00:00", "published_display": "17 Jun 2026 20:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood (IRWD) director Marla Kessler receives 63,481-share restricted stock grant", "summary": "Ironwood Pharmaceuticals director Marla L. Kessler was granted 63,481 shares of Class A Common Stock as restricted stock. This award was part of the company\u2019s non-employee director compensation policy and vests in full before the next annual stockholders' meeting. Following this ", "url": "https://www.stocktitan.net/sec-filings/IRWD/form-4-ironwood-pharmaceuticals-inc-insider-trading-activity-4adfd2baa273.html", "source_name": "Stock Titan", "published_at": "2026-06-17T21:09:19", "published_display": "17 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals (IRWD) director granted 63,481 restricted shares in latest Form 4", "summary": "Ironwood Pharmaceuticals director Jon R. Duane was granted 63,481 shares of Class A Common Stock as equity compensation, as disclosed in a recent Form 4 filing. These restricted shares, awarded at $0.00, will vest fully on the day before the next annual stockholders' meeting, inc", "url": "https://www.stocktitan.net/sec-filings/IRWD/form-4-ironwood-pharmaceuticals-inc-insider-trading-activity-676cd2f0a0b3.html", "source_name": "Stock Titan", "published_at": "2026-06-17T21:09:19", "published_display": "17 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood (NASDAQ: IRWD) director awarded restricted stock that vests before next meeting", "summary": "Ironwood Pharmaceuticals director Alexander J. Denner was awarded restricted Class A Common Stock as non-cash compensation, with two grants on June 15 and June 16, 2026, totaling 67,546 shares. These shares were issued under the company's Non-employee Director Compensation Policy", "url": "https://www.stocktitan.net/sec-filings/IRWD/form-4-ironwood-pharmaceuticals-inc-insider-trading-activity-6ceb0e5f5b25.html", "source_name": "Stock Titan", "published_at": "2026-06-17T21:09:19", "published_display": "17 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood (NASDAQ: IRWD) director sells shares and receives new stock grant", "summary": "Ironwood Pharmaceuticals Inc. director Julie McHugh reported both a sale and a grant of Class A Common Stock. She sold 21,571 shares at a weighted average price of $3.73 under a pre-arranged Rule 10b5-1 trading plan and received a grant of 63,481 restricted shares. After these tr", "url": "https://www.stocktitan.net/sec-filings/IRWD/form-4-ironwood-pharmaceuticals-inc-insider-trading-activity-86cd5709f78e.html", "source_name": "Stock Titan", "published_at": "2026-06-17T21:09:18", "published_display": "17 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals (IRWD) director receives 63,481-share grant", "summary": "Ironwood Pharmaceuticals director Mark G. Currie was granted 63,481 shares of Class A common stock as restricted stock, awarded at no cash cost as part of his director compensation. Following this award, Currie directly holds 676,900 shares of Ironwood common stock. The restricte", "url": "https://www.stocktitan.net/sec-filings/IRWD/form-4-ironwood-pharmaceuticals-inc-insider-trading-activity-f9344b4c532a.html", "source_name": "Stock Titan", "published_at": "2026-06-17T21:09:18", "published_display": "17 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] IRONWOOD PHARMACEUTICALS INC SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPalFOZGVLWVZSS2h0TGpnVG5FR09iR0dOX1FjVnJobF9rNFl3NFVVT09xMGFib3VWcXE3TDltZGJncUNvb2I2NnBYYzZKRkh3SWYxUkpMbHVSUnNicmg3UHZCRFI1bDhZYU9yZFk5WkdaUVV3OW1ZaTB3WURUcVRNWnRZOTdGaF9xSTQ2MFc0ZGxQYkJVRkZRWERoZ2dIWjhjMFhWd2NSWkg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T20:37:40+00:00", "published_display": "16 Jun 2026 20:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IRWD News | IRONWOOD PHARMACEUTICALS INC (NASDAQ:IRWD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE9jcnpUaGtLb2xqTlJDOWlHRjY2RjE4UlM3NDZBWVJJMW5DRW5yQ2ljYVRrWmlORVNnSlBrUDFfelVmRktpSTBkYzZoTjgtbWRzUHZTLThVWU53X0k?oc=5", "source_name": "ChartMill", "published_at": "2026-06-16T16:40:01+00:00", "published_display": "16 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals (IRWD) retires $200M 2026 convertible notes in cash", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNN0R5WXozWG5MdGoyOEQ1Vm42ZXA5bTduMWQxRjhNd1RRckZfMEwzbkc4dkFwNGd2WnlvMGVwTzJTS3lCTWJMc0p2QkhiOGVkRU54Y2lEQkhzSzdNS1RiUDNreE1oQ2tpdncxYTg0aGdCRTdwdTBOaDhpblFmQ3JkVDctNnZQSnkySjc1RlNmcWo1WHJHbGpxWXlQMV93dGRzelpQNlhVaS15cG9SRVR2YzF5aVZTWlA0?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T20:05:31+00:00", "published_display": "15 Jun 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Ironwood Pharmaceuticals, Inc. (IRWD) Strengthening Its Growth Outlook With Expanded Pediatric Approval for Linzess?", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQTlJJcmlOQV9zSnlqQVdTRklDX3JTX0FaTTNYVVl0MjBNWWRzdHJVak9oejZSamd0ZWVuNExqZzlGMC1QTktiSjJNeG1rWW11YUxXOVBJQjFSNUYwSi1kQTgzS1UtT05UOTdWYlA5Y3lsaF9ybEZCb0drbWR0MUlOOFotMFp3ajFrRXlUN3hDRlIyNklCVENZckIwMnFPRUk5ZXlGdmhBeElWX29rQ3l2THNFTHNuU1k?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals stock (US46333X1080): FDA clears new LINZESS use as shares trade steadily o", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQYWFVOGJ1a29KTzF6bkgtVjZ5RE9tWGMzdGJ0RXlDcDc3akEzXzlEYUpBUWZjVEV1Y3E1NFViN0RLQzdUSmdTNmlxd0F4R2VGMkVpUHJHWVJvb3d5YkVHR2dGaGN5anViRXpuUnRoSjVXQXA1MTBsTEpXYi1NaE9EcVNBeVNENmxBcnNCZHBiOGIyaUhjRFBvMWpBS2R1ZWZ1WlFGWlJBR3NHUi13SmRMeWxHT0hJLWRQcVdtOVB0OWg5N29hNm9PaQ?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals stock (US46333X1080): Nasdaq-listed GI specialist prepares for Q1 2026 inve", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPZ3M3dm5CXzJOSE96cFFiUzN4TkJ4dy1STWNwZjYyZ3ljMXJLdWI5LWlGWHcweFNCXzc0U2ZLTUQ3d0xVRHJVZmxZeGhFYUJqZktnbWtuRjBmejFPWExJS1MzS18taEhwZld0akhKRnRjRUxWMlFjbUg5S193eldHal9ISTVJUV9TaUNIMkVoSjFOak9vV1JuZEs0TldrU1p0SWxYQkFvVVFiUFp3VlVzT0YyY2JLN045UGlhV21odWhWa0JFQ0ZjY3dn?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ironwood-pharmaceuticals-participate-jefferies-global-200500098.html", "source_name": "Business Wire", "published_at": "2026-05-28T20:05:00+00:00", "published_display": "28 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Says US FDA Approves Linzess Use in Children Aged Two Years and Older With Functional Constipation", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ironwood-says-us-fda-approves-151137303.html", "source_name": "MT Newswires", "published_at": "2026-05-27T15:11:37+00:00", "published_display": "27 May 2026 15:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals (IRWD) sets interim CFO fee and RSU grant", "summary": "Ironwood Pharmaceuticals (IRWD) has amended a prior report to detail the compensation for Ronald Silver in his new role as interim chief financial officer. He will receive a monthly interim assignment fee of $12,250 and was granted 25,000 restricted stock units (RSUs) on May 19, ", "url": "https://www.stocktitan.net/sec-filings/IRWD/8-k-a-ironwood-pharmaceuticals-inc-amends-material-event-report-a6496f8b9f74.html", "source_name": "Stock Titan", "published_at": "2026-05-21T20:39:04", "published_display": "21 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood (IRWD) PFO Ronald Silver receives 25,000-share restricted stock grant", "summary": "Ronald Silver, PFO & PAO of Ironwood Pharmaceuticals Inc. (IRWD), has been granted 25,000 shares of restricted common stock as equity compensation. This award, valued at $0.00 per share, vests in two equal installments on each approximate anniversary of the grant date. Following ", "url": "https://www.stocktitan.net/sec-filings/IRWD/form-4-ironwood-pharmaceuticals-inc-insider-trading-activity-74b052dcbf47.html", "source_name": "Stock Titan", "published_at": "2026-05-21T20:12:53", "published_display": "21 May 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Ironwood Pharmaceuticals, Inc. (IRWD) a Comeback Pharma Stock After Major Earnings Improvement?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPRVRqOVdzWnZERDBKMUdjdFp3OUE4OHVHTU92MXVrZ2ZpRHFQWU1CTHdtUkhXV080X096Tm9zWDVldUl6dnYwdkFTQlB5Q3UxWnNIYVUtelVFU0hBcnZ2V0Znbld0dTFoWkNyeU51U3JtWTFFQnJiOWlLR0tjRUtuZURNM2xUbUZoN2lfNkJFOWxCRVU0TWpNSF9GWDA3elFfTDI3cHZ1dWdENWRpV094YQ?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week\u00ae 2026", "summary": "Ironwood Pharmaceuticals will present data from its LANDMARK survey at Digestive Disease Week\u00ae 2026, focusing on healthcare professionals' insights into the burden of total parenteral nutrition for short bowel syndrome patients. The company will also share long-term safety and to", "url": "https://www.businesswire.com/news/home/20260423319236/en/Ironwood-Pharmaceuticals-to-Share-Real-World-HCP-Perspectives-on-Burden-of-Total-Parenteral-Nutrition-in-Short-Bowel-Syndrome-SBS-at-Digestive-Disease-Week-2026", "source_name": "Business Wire", "published_at": "2026-05-17T07:39:43", "published_display": "17 May 2026 07:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals stock (US46333X1080): Q1 sales jump as LINZESS U.S. revenue rises", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNOGthMjRNU044bTJVRWlGaDVTRDE2TF9MaVBnNWdvUmNJX0hoUGlGaXhHNE5Vc09nWDFudHdlNWFfWHBjOHAtU2hqNjExYWtFYlpEZTEtLVF4ZGc5UmV0Skg1WGFmUnBqcWNST2hCMmVvcDVMY3VnREtGX3AySmt5VjRUSUlkY1l3RzFGT045ZWZYT1d5ZnFVR0t2OXJPcjktQTltZjI2TnY4VUVsNm5PN2NSWXlSTjFHQ2xiUktVVEdJS2x3UGc?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Armistice reports 15.03M Ironwood stake (NASDAQ: IRWD) in 13G/A", "summary": "Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 15,028,000 shares of Ironwood Pharmaceuticals (NASDAQ: IRWD) Class A common stock, representing 9.22% of the class, as detailed in an Amendment No. 6 to a Schedule 13G filing. Armistice Capital acts as t", "url": "https://www.stocktitan.net/sec-filings/IRWD/schedule-13g-a-ironwood-pharmaceuticals-inc-amended-passive-investmen-e02fd17bfe85.html", "source_name": "Stock Titan", "published_at": "2026-05-15T15:39:16", "published_display": "15 May 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals, Inc. - Class A Common Stock (NQ: IRWD", "summary": "This article provides recent news and financial updates for Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), including its stock performance. It compiles various news headlines from May to July 2021, covering topics like investor update calls, clinical trial results, business agree", "url": "https://markets.financialcontent.com/stocks/quote/news?CurrentPage=7&CSSURL=36.htm&Symbol=NQ%3AIRWD", "source_name": "FinancialContent", "published_at": "2026-05-15T04:39:16", "published_display": "15 May 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Renaissance reports 4.90% stake in Ironwood (IRWD)", "summary": "Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have reported a 4.90% beneficial stake in Ironwood Pharmaceuticals Inc. This stake amounts to 8,061,073 shares of Class A common stock, with both entities holding sole voting and sole dispositive power", "url": "https://www.stocktitan.net/sec-filings/IRWD/schedule-13g-a-ironwood-pharmaceuticals-inc-amended-passive-investmen-a9203dd27b74.html", "source_name": "Stock Titan", "published_at": "2026-05-14T21:10:21", "published_display": "14 May 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals, Inc. - Class A Common Stock (NQ: IRWD)", "summary": "This page provides recent news and press releases for Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), highlighting financial results, conference participation, and updates on their therapies and pipeline. Key announcements include strong quarterly results, maintenance of financial", "url": "https://markets.financialcontent.com/stocks/quote/news?ChannelType=PRESSRELEASES&CSSURL=36.htm&Symbol=537%3A10773079", "source_name": "FinancialContent", "published_at": "2026-05-14T19:10:21", "published_display": "14 May 2026 19:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals CFO Gregory Martini Resigns", "summary": "", "url": "https://finance.yahoo.com/news/ironwood-pharmaceuticals-cfo-gregory-martini-182132421.html", "source_name": "MT Newswires", "published_at": "2026-05-13T18:21:32+00:00", "published_display": "13 May 2026 18:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] IRONWOOD PHARMACEUTICALS INC Reports Material Event", "summary": "Ironwood Pharmaceuticals (IRWD) announced that its Senior Vice President and Chief Financial Officer, Gregory Martini, will resign effective May 15, 2026. The company stated this resignation is unrelated to any disagreement concerning its financial reporting. Ronald Silver, curre", "url": "https://www.stocktitan.net/sec-filings/IRWD/8-k-ironwood-pharmaceuticals-inc-reports-material-event-3b74172a3995.html", "source_name": "Stock Titan", "published_at": "2026-05-13T11:39:29", "published_display": "13 May 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharma stock drops after CFO exit (IRWD:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTFBSUWlHLUIwTDRLUU0wTEFZWmJpTW1CSmhuaVBGcFRVT09sWjcyeGpHRkV0OGpFVE9QMWtWVmY1Y0thQTh4MXhpSU00UjRBa0tiQUF1T3gxMHJCNU5FUnZHek81ZGU5QWRnVm4xZjZTX0pTaXB1d0FKX19jM2VDbEU?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Results: Ironwood Pharmaceuticals, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts", "summary": "Ironwood Pharmaceuticals (NASDAQ:IRWD) significantly beat revenue and earnings per share expectations in its latest quarterly report, leading to new forecasts from analysts. While analysts maintained similar revenue and EPS estimates for 2026, the price target for the stock rose ", "url": "https://www.sahmcapital.com/news/content/results-ironwood-pharmaceuticals-inc-beat-earnings-expectations-and-analysts-now-have-new-forecasts-2026-05-11", "source_name": "Sahm", "published_at": "2026-05-11T17:09:32", "published_display": "11 May 2026 17:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hikma Pharmaceuticals PLC stock (GB00B128J450): Dividend hike and $250M buyback", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNX2ZfWkxLZDAyQUZNRU55RXhPVHI4dlZrTVVuc3RlV01XV0Jqd21vSDdYU0l3QkJOejBicXhjRXhQcmpkZHlVQ3BsRFE5ZFFxbFV3MWgtLUpndEZKTm1vbTAwaGlYMHEzWVVjNDVUYjFpM1hJS0NRTjdCc3pOeG9VNlg0QThScXpuV3lYNi0xY2NXMnkwdkFMYU8xYWU0WTIyaVdESzRVV2wxaThRazh6bTZCV1RPMWpJWW0tZy1qQUJVNjh6?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals Inc - Ordinary Shares - Class A (IRWD) News, Articles, Events & Latest Updates", "summary": "This article provides news and updates for Ironwood Pharmaceuticals Inc (IRWD), including recent financial performance and upcoming events. Despite beating Q1 earnings and revenue estimates driven by strong LINZESS sales, the stock experienced a slight dip. The company continues ", "url": "https://stocktwits.com/symbol/IRWD/news", "source_name": "Stocktwits", "published_at": "2026-05-09T16:39:29", "published_display": "09 May 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals (IRWD) Q1 Profit Of US$40.8 Million Tests Bearish Earnings-Decline Narrative", "summary": "Ironwood Pharmaceuticals (IRWD) reported a Q1 profit of US$40.8 million, challenging a bearish earnings-decline narrative with US$106.5 million in revenue and US$0.25 basic EPS. While bulls point to a profitable trailing twelve-month profile, bears highlight fluctuating quarterly", "url": "https://www.sahmcapital.com/news/content/ironwood-pharmaceuticals-irwd-q1-profit-of-us408-million-tests-bearish-earnings-decline-narrative-2026-05-08", "source_name": "Sahm", "published_at": "2026-05-09T03:39:28", "published_display": "09 May 2026 03:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/ed5eca12-b1a3-3669-a530-d48ab0000a2c/ironwood-pharmaceuticals-q1.html", "source_name": "MarketBeat", "published_at": "2026-05-08T05:07:54+00:00", "published_display": "08 May 2026 05:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood (IRWD) turns loss to profit as LINZESS drives Q1 2026 revenue surge", "summary": "Ironwood Pharmaceuticals (IRWD) reported a significant financial turnaround in Q1 2026, swinging from a net loss to a profit, primarily driven by a substantial increase in LINZESS revenue. Total revenues surged to $106.5 million from $41.1 million year-over-year, leading to a dil", "url": "https://www.stocktitan.net/sec-filings/IRWD/10-q-ironwood-pharmaceuticals-inc-quarterly-earnings-report-66818d72c832.html", "source_name": "Stock Titan", "published_at": "2026-05-08T04:39:21", "published_display": "08 May 2026 04:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood says LINZESS brought in $273M as FDA reviews use in kids", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQaTkxc05ZZHhJbEItR2FVeFNzSW1oQ2xHQXlRb1JMSGJORE1FalQzWG9ZbDFIVmNfY2toYW5nX2xnWmNWa0xjZ1ktdTQwYUdJLWxxVkx1NzRtZmR2Y3N3OWQtTy03Rzc5OEc5elRCT3czMG9oSzNPMVl1MFI0dllOc3c2Y1VTSEVYQmFnZHM0Qm94ZFV3M21PQnMyTkd5M2tzWUlKRURUSFlyWUFSakJwcTlYbmE5NFFlbERpLVZB?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals (IRWD) price target increased by 28.97% to 7.04", "summary": "This article reports that the price target for Ironwood Pharmaceuticals (IRWD) has been increased by 28.97%, bringing it to $7.04. The content provided is minimal, offering only this specific financial update without further details or analysis.", "url": "https://www.msn.com/en-us/money/topstocks/ironwood-pharmaceuticals-irwd-price-target-increased-by-28-97-to-7-04/ar-AA21UFr8?ocid=finance-verthp-feeds", "source_name": "MSN", "published_at": "2026-05-05T05:39:06", "published_display": "05 May 2026 05:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOZ3VWYklhSU5ycTZzaF80Z0ExamNYOWdEdzQ5OVMwSko4UzdKM3pQMWZGTlR6QXJYMlJGUEFkbHhnOUJDNGpaRkZFRUZuMHZ3QVVjaktWeng4OWRVYnU5MWxzQnJNUXFwTF9mcVdwUEMxMFl4ZHBBY0hoaTFudm9GQTRQM3RydVlhVnFTTUVyem1VcnFkZWx4bDBhSlVEM0owOWJJQXRZMGNTZW9DUElyN3NDZWp5OTRoTFh1MzlFMA?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood (NASDAQ: IRWD) seeks 10M more equity plan shares in 2026 proxy", "summary": "Ironwood Pharmaceuticals is proposing an amendment to its Amended and Restated 2019 Equity Incentive Plan to add 10,000,000 shares for equity awards, seeking stockholder approval at its 2026 annual meeting on June 16, 2026. The company emphasizes the necessity of this increase to", "url": "https://www.stocktitan.net/sec-filings/IRWD/def-14a-ironwood-pharmaceuticals-inc-definitive-proxy-statement-4b2a5c9cf462.html", "source_name": "Stock Titan", "published_at": "2026-04-28T23:09:06", "published_display": "28 Apr 2026 23:09", "sentiment": "positive", "sentiment_pct": 61, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Book value per share of Ironwood Pharmaceuticals, Inc. Class A \u2013 SWB:I76", "summary": "The article focuses on the book value per share of Ironwood Pharmaceuticals, Inc. Class A (SWB:I76), traded on the Stuttgart Stock Exchange. It provides financial data and a general overview of the company's financials for various periods, without delving into specific numbers in", "url": "https://www.tradingview.com/symbols/SWB-I76/financials-statistics-and-ratios/book-value-per-share/", "source_name": "TradingView", "published_at": "2026-04-28T07:39:27", "published_display": "28 Apr 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bank of America (NASDAQ: IRWD) reports 6.1% stake in Ironwood Pharmaceuticals", "summary": "Bank of America Corporation has disclosed a 6.1% beneficial ownership stake in Ironwood Pharmaceuticals (NASDAQ: IRWD), totaling 9,962,355 Class A Common Stock shares. This information comes from a Schedule 13G/A filing, referencing 163,058,316 outstanding shares as of January 31", "url": "https://www.stocktitan.net/sec-filings/IRWD/schedule-13g-a-ironwood-pharmaceuticals-inc-amended-passive-investmen-4693d838cccb.html", "source_name": "Stock Titan", "published_at": "2026-04-27T17:10:34", "published_display": "27 Apr 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Vanguard Group (NASDAQ: IRWD) reports zero beneficial ownership after realignment", "summary": "The Vanguard Group filed an amendment to its Schedule 13G/A report, declaring zero beneficial ownership of Ironwood Pharmaceuticals Inc. common stock. This change is due to an internal realignment effective January 12, 2026, where certain Vanguard subsidiaries will now report the", "url": "https://www.stocktitan.net/sec-filings/IRWD/schedule-13g-a-ironwood-pharmaceuticals-inc-amended-passive-investmen-9e7e76d1fbbc.html", "source_name": "Stock Titan", "published_at": "2026-03-29T03:39:53", "published_display": "29 Mar 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Ironwood (IRWD) Down 13.9% Since Last Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNNVI1eEMyOWhDdnNCS21TT0p5MjFNTW5MOEtOdG0yOGlZTVdVQTE1NVBxR21BRjh5elFscHJuTlNXR3FXeDZDQjA0NHBnTV9aTkxKYkZjOTZyWVBfVmRuYVVQWUV0cjlFcnNicy1ZcnEzRDY0R2NzREktUFlFVzU0bTFTRnNLbXZkV0VORDQwdHBPU3No?oc=5", "source_name": "Market source", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarissa Capital (IRWD) cuts Ironwood stake with 6.7M-share sale, keeps 5.8%", "summary": "Sarissa Capital Management LP and Alexander J. Denner have reduced their stake in Ironwood Pharmaceuticals (IRWD) through the sale of 6.7 million shares on March 17, 2026, for over $20.5 million. Despite the significant sale, Sarissa Capital still beneficially owns 5.6% of Ironwo", "url": "https://www.stocktitan.net/sec-filings/IRWD/schedule-13d-a-ironwood-pharmaceuticals-inc-amended-major-shareholder-56edba5b60da.html", "source_name": "Stock Titan", "published_at": "2026-03-19T22:40:33", "published_display": "19 Mar 2026 22:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals director Denner sells $20.5m in shares", "summary": "Ironwood Pharmaceuticals director Alexander J. Denner sold $20.5 million worth of Class A Common Stock on March 17, 2026, amidst recent stock volatility. Despite this insider sale, InvestingPro analysis suggests the stock is undervalued, and analysts like Jefferies and Citizens h", "url": "https://m.uk.investing.com/news/insider-trading-news/ironwood-pharmaceuticals-director-denner-sells-205m-in-shares-93CH-4564712?ampMode=1", "source_name": "Investing.com UK", "published_at": "2026-03-18T18:39:28", "published_display": "18 Mar 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals director Denner sells $20.5m in shares By Investing.com", "summary": "Ironwood Pharmaceuticals director Alexander J. Denner sold $20.5 million worth of Class A Common Stock on March 17, 2026, amidst recent stock volatility but a significant yearly gain. Despite the insider sale, InvestingPro analysis indicates the stock is undervalued, and several ", "url": "https://za.investing.com/news/insider-trading-news/ironwood-pharmaceuticals-director-denner-sells-205m-in-shares-93CH-4170170", "source_name": "Investing.com South Africa", "published_at": "2026-03-18T07:39:46", "published_display": "18 Mar 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarissa funds trim Ironwood (NASDAQ: IRWD) stake with 6.7M-share sale", "summary": "Investment vehicles advised by Sarissa Capital Management LP, associated with director Alexander J. Denner, sold off 6.7 million shares of Ironwood Pharmaceuticals (NASDAQ: IRWD) Class A Common Stock on March 17, 2026, at prices between $3.05 and $3.31 per share. This major sale ", "url": "https://www.stocktitan.net/sec-filings/IRWD/form-4-ironwood-pharmaceuticals-inc-insider-trading-activity-58e7fb54828d.html", "source_name": "Stock Titan", "published_at": "2026-03-18T01:09:13", "published_display": "18 Mar 2026 01:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals (IRWD) CFO receives 136,612-share stock grant", "summary": "Ironwood Pharmaceuticals (IRWD) CFO Gregory S. Martini received an equity compensation grant of 136,612 shares of Class A Common Stock on March 10, 2026. This award is in the form of restricted stock units, vesting in four equal installments over approximate anniversaries of the ", "url": "https://www.stocktitan.net/sec-filings/IRWD/form-4-ironwood-pharmaceuticals-inc-insider-trading-activity-d3ec7dc276ef.html", "source_name": "Stock Titan", "published_at": "2026-03-16T08:09:33", "published_display": "16 Mar 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood (NASDAQ: IRWD) CCO granted 136,612 restricted shares as equity award", "summary": "Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) Chief Commercial Officer Tammi L. Gaskins was granted 136,612 restricted shares of Class A Common Stock as an equity award. This compensation award vests in four equal annual installments, tying the value to continued service and perf", "url": "https://www.stocktitan.net/sec-filings/IRWD/form-4-ironwood-pharmaceuticals-inc-insider-trading-activity-c7eccaf99336.html", "source_name": "Stock Titan", "published_at": "2026-03-15T10:39:34", "published_display": "15 Mar 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood (NASDAQ: IRWD) CEO receives 409,836-share restricted stock award", "summary": "Ironwood Pharmaceuticals (NASDAQ: IRWD) CEO Thomas A. McCourt was granted a restricted stock unit award of 409,836 shares of Class A Common Stock. This annual performance award, valued at $0 per share, vests in three equal installments on each approximate anniversary of the grant", "url": "https://www.stocktitan.net/sec-filings/IRWD/form-4-ironwood-pharmaceuticals-inc-insider-trading-activity-0490eea8cf0a.html", "source_name": "Stock Titan", "published_at": "2026-03-13T18:09:42", "published_display": "13 Mar 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Ironwood Pharmaceuticals Stock Skyrocket Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOY1hVMGx1dmwwaHlmTnFrR0VHT3FUbGlsMFNrZUJEcnpCaHczMVZFb1hwdk1xWkY0Z0p5SWZQeV9IX2lUSGNfVWpVbHlDblhna0hLRTdhOUR6Z0xZa1BfYXJOdGdkd2txYk9Bd3VZb3hjNDd0eV9ZRmJiTGRFaE9sbmpETm5rRUNrYUJEbDBZalJYUjR2OVY2U25jUHlLSE80d09iWDhrNURUT2F0?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals: Downgrading On Pipeline Setback And Extended Timeline For Apraglutide", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOS2JfVkMwTE5FNHJoeUJwMEFtT3lKamQ2QzdQRFRpNTFyYXNFeXZHSV9hN2ZfRDZOUk1CMkRwaUdWRVk4ODRiTUJ5eDJUbWNFSGtiUVZfNURtRXdFNHJmVEVhd2Vidk9aU2JRbkpWYWdMSlhrNlM2N0dUVUNRV2ItZU9Ec1pHSzBGdW92OU5PTU45NXYzbW9ZRGdra1Q0Sk0yeEpsVl9XelFNWVl4T1liRThRT2s4VkxHdlRFVVJleEM5ZkxqWG9n?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood vs. Bausch Health: Which GI Drug Stock is a Better Pick Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE9XaEtqYWpwalIyaUxWWUlpem9pSUJTWEo1UmtPel81VjUwaHRNMzFGVTVPQ1huQXp5dEJ0SFdJUzBwTzJjS2RYUFk3NTFUVm1WRk94REt6WG1CeURmOS1qZ0pCN3E2d3h0NW9JMXhZbF9SUmpFdWo4RHF3QWpGWDg?oc=5", "source_name": "Market source", "published_at": "2026-02-20T08:00:00+00:00", "published_display": "20 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Shares Bounce 32% But Its Business Still Trails The Industry", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-06T08:00:00+00:00", "published_display": "06 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Ironwood Pharmaceuticals (IRWD) Is Up 37.8% After New 2026 Guidance And Ferring Settlement", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-06T08:00:00+00:00", "published_display": "06 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Need To Know: Analysts Are Much More Bullish On Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Revenues", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-12T08:00:00+00:00", "published_display": "12 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxPU01qVk1jRkRUTm9kbjhnb1hReG1iSmR5UEhVY255Y1RpYVBKODBwSHltVjhaZ3NsWDFVVHdreFRCdktvb2dkMmtqd2RtelI5RUlEMWRnU3JySU9GZ194b2pkOXRCZ1BsRmo3WFBtRWZpSHRIdF9rQllLb2ZhSTUtX3FOdFdMWjY5S0tQdUkyR2duT3BFX3RSRlZ5ZTUtY2ZXVjRUQzNlVWNjSi1RQWZmVFlia1VzM05GWEJ2QmJNOWtkRnhyd2ZtYk9aeS1aRWlpdG1meDRmZkxNUzBP?oc=5", "source_name": "BioSpace", "published_at": "2025-08-07T07:00:00+00:00", "published_display": "07 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswJBVV95cUxQaVpuWmR2RmZnRGpUT3hrOVVoOHFaTjU5NnN6SFBSZjZQOGgzQjlfaGcwVERFV09iLVdnYndKRmxEVWZSS2R3dWwxSnZKdEdZR1ZNejZKNG05VzhEakZwRmJGZ0pWanQ2dXFVaHhtN21lVmZpaEY5OGZDcXFDSVZGSjE4MUJlRXl4TzF4RlM4amc0X1VvN1k0NFk2RU40dmRqQ0tQWTNhTWt4OFVFVV9wbFFSdTZ6d1BRM3NmVmNIdXM2VkJiRXM1OFpvOVp3X3IwZ0JwVHU1QjZ6bmZXenVpRko3dlNnQXVWWDQwMVpLRmFiS25ldkFfS3kxeG9iX1B2UzRVV0hMZC1BQU5Ub3ZScmxkQTdzRlE5a3k2RmViR0h2NC1BUWp3NmR0cVpSdDg1Y2RV?oc=5", "source_name": "Ironwood Pharmaceuticals", "published_at": "2025-04-25T07:00:00+00:00", "published_display": "25 Apr 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Ironwood Pharmaceuticals (IRWD) adds 10M shares to 2019 equity incentive plan", "summary": "Ironwood Pharmaceuticals (IRWD) announced that its stockholders approved an amendment to the 2019 Equity Incentive Plan, adding 10 million shares of Class A common stock for future equity-based compensation. This approval occurred at the 2026 Annual Meeting of Stockholders, where", "url": "https://www.stocktitan.net/sec-filings/IRWD/8-k-ironwood-pharmaceuticals-inc-reports-material-event-b2fcb635b377.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:14:32", "published_display": "18 Jun 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood (IRWD) director Jay Shepard receives 63,481-share restricted stock grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPdzNFZVdwd3lTQUZSQXNTVTNFV2ZHX3U3b0x2VnJBQnRJbzllMDBySjFtVUpnWExPMWNHaHplTHlQTFlqdXU3QnYwUUNHNjRSNFRpdDZyVnhJMWszYllVc2lOLWdlY2paZ3BfRmJsLTc1c05hSk5TUkN6eGZIX0xVQXBnelNidE94Z0lDUm1FdVl2Ti0yNENBSjFfUGZHWUg5VWlUSUhCVTgwdDlyb0NrYm56WHJRWjdXTTVyYm9PNA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T20:47:05+00:00", "published_display": "17 Jun 2026 20:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Catherine Moukheibir receives 63,481 Ironwood (IRWD) restricted shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQSWwzaE1rQ1Q1WHI0MlZNSUZzU2cxbWZHQUZQYWVyYWs4VG5ENmkzRFRYYVJiSG0tTFpGbksxT2tQOTFlRWZWWW1RVnNRb2ZPdF94QWpiOHJZdzVVMTNKbU1iNWhhMnRpYWZrcEhuaVJ6c0RBcVFtUXdGYWZ1R0tJV2oxVHQ4OFFSMG5XUUc1b212ek5mR240SVhNRDdjLUJDY0kxZmhHYVNhOFhLRXVkT3l6YzI2eDcxVExPQmpMQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T20:36:28+00:00", "published_display": "17 Jun 2026 20:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood (IRWD) director Marla Kessler receives 63,481-share restricted stock grant", "summary": "Ironwood Pharmaceuticals director Marla L. Kessler was granted 63,481 shares of Class A Common Stock as restricted stock. This award was part of the company\u2019s non-employee director compensation policy and vests in full before the next annual stockholders' meeting. Following this ", "url": "https://www.stocktitan.net/sec-filings/IRWD/form-4-ironwood-pharmaceuticals-inc-insider-trading-activity-4adfd2baa273.html", "source_name": "Stock Titan", "published_at": "2026-06-17T21:09:19", "published_display": "17 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals (IRWD) director granted 63,481 restricted shares in latest Form 4", "summary": "Ironwood Pharmaceuticals director Jon R. Duane was granted 63,481 shares of Class A Common Stock as equity compensation, as disclosed in a recent Form 4 filing. These restricted shares, awarded at $0.00, will vest fully on the day before the next annual stockholders' meeting, inc", "url": "https://www.stocktitan.net/sec-filings/IRWD/form-4-ironwood-pharmaceuticals-inc-insider-trading-activity-676cd2f0a0b3.html", "source_name": "Stock Titan", "published_at": "2026-06-17T21:09:19", "published_display": "17 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood (NASDAQ: IRWD) director awarded restricted stock that vests before next meeting", "summary": "Ironwood Pharmaceuticals director Alexander J. Denner was awarded restricted Class A Common Stock as non-cash compensation, with two grants on June 15 and June 16, 2026, totaling 67,546 shares. These shares were issued under the company's Non-employee Director Compensation Policy", "url": "https://www.stocktitan.net/sec-filings/IRWD/form-4-ironwood-pharmaceuticals-inc-insider-trading-activity-6ceb0e5f5b25.html", "source_name": "Stock Titan", "published_at": "2026-06-17T21:09:19", "published_display": "17 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood (NASDAQ: IRWD) director sells shares and receives new stock grant", "summary": "Ironwood Pharmaceuticals Inc. director Julie McHugh reported both a sale and a grant of Class A Common Stock. She sold 21,571 shares at a weighted average price of $3.73 under a pre-arranged Rule 10b5-1 trading plan and received a grant of 63,481 restricted shares. After these tr", "url": "https://www.stocktitan.net/sec-filings/IRWD/form-4-ironwood-pharmaceuticals-inc-insider-trading-activity-86cd5709f78e.html", "source_name": "Stock Titan", "published_at": "2026-06-17T21:09:18", "published_display": "17 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals (IRWD) director receives 63,481-share grant", "summary": "Ironwood Pharmaceuticals director Mark G. Currie was granted 63,481 shares of Class A common stock as restricted stock, awarded at no cash cost as part of his director compensation. Following this award, Currie directly holds 676,900 shares of Ironwood common stock. The restricte", "url": "https://www.stocktitan.net/sec-filings/IRWD/form-4-ironwood-pharmaceuticals-inc-insider-trading-activity-f9344b4c532a.html", "source_name": "Stock Titan", "published_at": "2026-06-17T21:09:18", "published_display": "17 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] IRONWOOD PHARMACEUTICALS INC SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPalFOZGVLWVZSS2h0TGpnVG5FR09iR0dOX1FjVnJobF9rNFl3NFVVT09xMGFib3VWcXE3TDltZGJncUNvb2I2NnBYYzZKRkh3SWYxUkpMbHVSUnNicmg3UHZCRFI1bDhZYU9yZFk5WkdaUVV3OW1ZaTB3WURUcVRNWnRZOTdGaF9xSTQ2MFc0ZGxQYkJVRkZRWERoZ2dIWjhjMFhWd2NSWkg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T20:37:40+00:00", "published_display": "16 Jun 2026 20:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IRWD News | IRONWOOD PHARMACEUTICALS INC (NASDAQ:IRWD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE9jcnpUaGtLb2xqTlJDOWlHRjY2RjE4UlM3NDZBWVJJMW5DRW5yQ2ljYVRrWmlORVNnSlBrUDFfelVmRktpSTBkYzZoTjgtbWRzUHZTLThVWU53X0k?oc=5", "source_name": "ChartMill", "published_at": "2026-06-16T16:40:01+00:00", "published_display": "16 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals (IRWD) retires $200M 2026 convertible notes in cash", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNN0R5WXozWG5MdGoyOEQ1Vm42ZXA5bTduMWQxRjhNd1RRckZfMEwzbkc4dkFwNGd2WnlvMGVwTzJTS3lCTWJMc0p2QkhiOGVkRU54Y2lEQkhzSzdNS1RiUDNreE1oQ2tpdncxYTg0aGdCRTdwdTBOaDhpblFmQ3JkVDctNnZQSnkySjc1RlNmcWo1WHJHbGpxWXlQMV93dGRzelpQNlhVaS15cG9SRVR2YzF5aVZTWlA0?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T20:05:31+00:00", "published_display": "15 Jun 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Ironwood Pharmaceuticals, Inc. (IRWD) Strengthening Its Growth Outlook With Expanded Pediatric Approval for Linzess?", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQTlJJcmlOQV9zSnlqQVdTRklDX3JTX0FaTTNYVVl0MjBNWWRzdHJVak9oejZSamd0ZWVuNExqZzlGMC1QTktiSjJNeG1rWW11YUxXOVBJQjFSNUYwSi1kQTgzS1UtT05UOTdWYlA5Y3lsaF9ybEZCb0drbWR0MUlOOFotMFp3ajFrRXlUN3hDRlIyNklCVENZckIwMnFPRUk5ZXlGdmhBeElWX29rQ3l2THNFTHNuU1k?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals stock (US46333X1080): FDA clears new LINZESS use as shares trade steadily o", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQYWFVOGJ1a29KTzF6bkgtVjZ5RE9tWGMzdGJ0RXlDcDc3akEzXzlEYUpBUWZjVEV1Y3E1NFViN0RLQzdUSmdTNmlxd0F4R2VGMkVpUHJHWVJvb3d5YkVHR2dGaGN5anViRXpuUnRoSjVXQXA1MTBsTEpXYi1NaE9EcVNBeVNENmxBcnNCZHBiOGIyaUhjRFBvMWpBS2R1ZWZ1WlFGWlJBR3NHUi13SmRMeWxHT0hJLWRQcVdtOVB0OWg5N29hNm9PaQ?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals stock (US46333X1080): Nasdaq-listed GI specialist prepares for Q1 2026 inve", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPZ3M3dm5CXzJOSE96cFFiUzN4TkJ4dy1STWNwZjYyZ3ljMXJLdWI5LWlGWHcweFNCXzc0U2ZLTUQ3d0xVRHJVZmxZeGhFYUJqZktnbWtuRjBmejFPWExJS1MzS18taEhwZld0akhKRnRjRUxWMlFjbUg5S193eldHal9ISTVJUV9TaUNIMkVoSjFOak9vV1JuZEs0TldrU1p0SWxYQkFvVVFiUFp3VlVzT0YyY2JLN045UGlhV21odWhWa0JFQ0ZjY3dn?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ironwood-pharmaceuticals-participate-jefferies-global-200500098.html", "source_name": "Business Wire", "published_at": "2026-05-28T20:05:00+00:00", "published_display": "28 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Says US FDA Approves Linzess Use in Children Aged Two Years and Older With Functional Constipation", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ironwood-says-us-fda-approves-151137303.html", "source_name": "MT Newswires", "published_at": "2026-05-27T15:11:37+00:00", "published_display": "27 May 2026 15:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals (IRWD) sets interim CFO fee and RSU grant", "summary": "Ironwood Pharmaceuticals (IRWD) has amended a prior report to detail the compensation for Ronald Silver in his new role as interim chief financial officer. He will receive a monthly interim assignment fee of $12,250 and was granted 25,000 restricted stock units (RSUs) on May 19, ", "url": "https://www.stocktitan.net/sec-filings/IRWD/8-k-a-ironwood-pharmaceuticals-inc-amends-material-event-report-a6496f8b9f74.html", "source_name": "Stock Titan", "published_at": "2026-05-21T20:39:04", "published_display": "21 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood (IRWD) PFO Ronald Silver receives 25,000-share restricted stock grant", "summary": "Ronald Silver, PFO & PAO of Ironwood Pharmaceuticals Inc. (IRWD), has been granted 25,000 shares of restricted common stock as equity compensation. This award, valued at $0.00 per share, vests in two equal installments on each approximate anniversary of the grant date. Following ", "url": "https://www.stocktitan.net/sec-filings/IRWD/form-4-ironwood-pharmaceuticals-inc-insider-trading-activity-74b052dcbf47.html", "source_name": "Stock Titan", "published_at": "2026-05-21T20:12:53", "published_display": "21 May 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Ironwood Pharmaceuticals, Inc. (IRWD) a Comeback Pharma Stock After Major Earnings Improvement?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPRVRqOVdzWnZERDBKMUdjdFp3OUE4OHVHTU92MXVrZ2ZpRHFQWU1CTHdtUkhXV080X096Tm9zWDVldUl6dnYwdkFTQlB5Q3UxWnNIYVUtelVFU0hBcnZ2V0Znbld0dTFoWkNyeU51U3JtWTFFQnJiOWlLR0tjRUtuZURNM2xUbUZoN2lfNkJFOWxCRVU0TWpNSF9GWDA3elFfTDI3cHZ1dWdENWRpV094YQ?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week\u00ae 2026", "summary": "Ironwood Pharmaceuticals will present data from its LANDMARK survey at Digestive Disease Week\u00ae 2026, focusing on healthcare professionals' insights into the burden of total parenteral nutrition for short bowel syndrome patients. The company will also share long-term safety and to", "url": "https://www.businesswire.com/news/home/20260423319236/en/Ironwood-Pharmaceuticals-to-Share-Real-World-HCP-Perspectives-on-Burden-of-Total-Parenteral-Nutrition-in-Short-Bowel-Syndrome-SBS-at-Digestive-Disease-Week-2026", "source_name": "Business Wire", "published_at": "2026-05-17T07:39:43", "published_display": "17 May 2026 07:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals stock (US46333X1080): Q1 sales jump as LINZESS U.S. revenue rises", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNOGthMjRNU044bTJVRWlGaDVTRDE2TF9MaVBnNWdvUmNJX0hoUGlGaXhHNE5Vc09nWDFudHdlNWFfWHBjOHAtU2hqNjExYWtFYlpEZTEtLVF4ZGc5UmV0Skg1WGFmUnBqcWNST2hCMmVvcDVMY3VnREtGX3AySmt5VjRUSUlkY1l3RzFGT045ZWZYT1d5ZnFVR0t2OXJPcjktQTltZjI2TnY4VUVsNm5PN2NSWXlSTjFHQ2xiUktVVEdJS2x3UGc?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Armistice reports 15.03M Ironwood stake (NASDAQ: IRWD) in 13G/A", "summary": "Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 15,028,000 shares of Ironwood Pharmaceuticals (NASDAQ: IRWD) Class A common stock, representing 9.22% of the class, as detailed in an Amendment No. 6 to a Schedule 13G filing. Armistice Capital acts as t", "url": "https://www.stocktitan.net/sec-filings/IRWD/schedule-13g-a-ironwood-pharmaceuticals-inc-amended-passive-investmen-e02fd17bfe85.html", "source_name": "Stock Titan", "published_at": "2026-05-15T15:39:16", "published_display": "15 May 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals, Inc. - Class A Common Stock (NQ: IRWD", "summary": "This article provides recent news and financial updates for Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), including its stock performance. It compiles various news headlines from May to July 2021, covering topics like investor update calls, clinical trial results, business agree", "url": "https://markets.financialcontent.com/stocks/quote/news?CurrentPage=7&CSSURL=36.htm&Symbol=NQ%3AIRWD", "source_name": "FinancialContent", "published_at": "2026-05-15T04:39:16", "published_display": "15 May 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Renaissance reports 4.90% stake in Ironwood (IRWD)", "summary": "Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have reported a 4.90% beneficial stake in Ironwood Pharmaceuticals Inc. This stake amounts to 8,061,073 shares of Class A common stock, with both entities holding sole voting and sole dispositive power", "url": "https://www.stocktitan.net/sec-filings/IRWD/schedule-13g-a-ironwood-pharmaceuticals-inc-amended-passive-investmen-a9203dd27b74.html", "source_name": "Stock Titan", "published_at": "2026-05-14T21:10:21", "published_display": "14 May 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals, Inc. - Class A Common Stock (NQ: IRWD)", "summary": "This page provides recent news and press releases for Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), highlighting financial results, conference participation, and updates on their therapies and pipeline. Key announcements include strong quarterly results, maintenance of financial", "url": "https://markets.financialcontent.com/stocks/quote/news?ChannelType=PRESSRELEASES&CSSURL=36.htm&Symbol=537%3A10773079", "source_name": "FinancialContent", "published_at": "2026-05-14T19:10:21", "published_display": "14 May 2026 19:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals CFO Gregory Martini Resigns", "summary": "", "url": "https://finance.yahoo.com/news/ironwood-pharmaceuticals-cfo-gregory-martini-182132421.html", "source_name": "MT Newswires", "published_at": "2026-05-13T18:21:32+00:00", "published_display": "13 May 2026 18:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] IRONWOOD PHARMACEUTICALS INC Reports Material Event", "summary": "Ironwood Pharmaceuticals (IRWD) announced that its Senior Vice President and Chief Financial Officer, Gregory Martini, will resign effective May 15, 2026. The company stated this resignation is unrelated to any disagreement concerning its financial reporting. Ronald Silver, curre", "url": "https://www.stocktitan.net/sec-filings/IRWD/8-k-ironwood-pharmaceuticals-inc-reports-material-event-3b74172a3995.html", "source_name": "Stock Titan", "published_at": "2026-05-13T11:39:29", "published_display": "13 May 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharma stock drops after CFO exit (IRWD:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTFBSUWlHLUIwTDRLUU0wTEFZWmJpTW1CSmhuaVBGcFRVT09sWjcyeGpHRkV0OGpFVE9QMWtWVmY1Y0thQTh4MXhpSU00UjRBa0tiQUF1T3gxMHJCNU5FUnZHek81ZGU5QWRnVm4xZjZTX0pTaXB1d0FKX19jM2VDbEU?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Results: Ironwood Pharmaceuticals, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts", "summary": "Ironwood Pharmaceuticals (NASDAQ:IRWD) significantly beat revenue and earnings per share expectations in its latest quarterly report, leading to new forecasts from analysts. While analysts maintained similar revenue and EPS estimates for 2026, the price target for the stock rose ", "url": "https://www.sahmcapital.com/news/content/results-ironwood-pharmaceuticals-inc-beat-earnings-expectations-and-analysts-now-have-new-forecasts-2026-05-11", "source_name": "Sahm", "published_at": "2026-05-11T17:09:32", "published_display": "11 May 2026 17:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hikma Pharmaceuticals PLC stock (GB00B128J450): Dividend hike and $250M buyback", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNX2ZfWkxLZDAyQUZNRU55RXhPVHI4dlZrTVVuc3RlV01XV0Jqd21vSDdYU0l3QkJOejBicXhjRXhQcmpkZHlVQ3BsRFE5ZFFxbFV3MWgtLUpndEZKTm1vbTAwaGlYMHEzWVVjNDVUYjFpM1hJS0NRTjdCc3pOeG9VNlg0QThScXpuV3lYNi0xY2NXMnkwdkFMYU8xYWU0WTIyaVdESzRVV2wxaThRazh6bTZCV1RPMWpJWW0tZy1qQUJVNjh6?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals Inc - Ordinary Shares - Class A (IRWD) News, Articles, Events & Latest Updates", "summary": "This article provides news and updates for Ironwood Pharmaceuticals Inc (IRWD), including recent financial performance and upcoming events. Despite beating Q1 earnings and revenue estimates driven by strong LINZESS sales, the stock experienced a slight dip. The company continues ", "url": "https://stocktwits.com/symbol/IRWD/news", "source_name": "Stocktwits", "published_at": "2026-05-09T16:39:29", "published_display": "09 May 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals (IRWD) Q1 Profit Of US$40.8 Million Tests Bearish Earnings-Decline Narrative", "summary": "Ironwood Pharmaceuticals (IRWD) reported a Q1 profit of US$40.8 million, challenging a bearish earnings-decline narrative with US$106.5 million in revenue and US$0.25 basic EPS. While bulls point to a profitable trailing twelve-month profile, bears highlight fluctuating quarterly", "url": "https://www.sahmcapital.com/news/content/ironwood-pharmaceuticals-irwd-q1-profit-of-us408-million-tests-bearish-earnings-decline-narrative-2026-05-08", "source_name": "Sahm", "published_at": "2026-05-09T03:39:28", "published_display": "09 May 2026 03:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/ed5eca12-b1a3-3669-a530-d48ab0000a2c/ironwood-pharmaceuticals-q1.html", "source_name": "MarketBeat", "published_at": "2026-05-08T05:07:54+00:00", "published_display": "08 May 2026 05:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood (IRWD) turns loss to profit as LINZESS drives Q1 2026 revenue surge", "summary": "Ironwood Pharmaceuticals (IRWD) reported a significant financial turnaround in Q1 2026, swinging from a net loss to a profit, primarily driven by a substantial increase in LINZESS revenue. Total revenues surged to $106.5 million from $41.1 million year-over-year, leading to a dil", "url": "https://www.stocktitan.net/sec-filings/IRWD/10-q-ironwood-pharmaceuticals-inc-quarterly-earnings-report-66818d72c832.html", "source_name": "Stock Titan", "published_at": "2026-05-08T04:39:21", "published_display": "08 May 2026 04:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood says LINZESS brought in $273M as FDA reviews use in kids", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQaTkxc05ZZHhJbEItR2FVeFNzSW1oQ2xHQXlRb1JMSGJORE1FalQzWG9ZbDFIVmNfY2toYW5nX2xnWmNWa0xjZ1ktdTQwYUdJLWxxVkx1NzRtZmR2Y3N3OWQtTy03Rzc5OEc5elRCT3czMG9oSzNPMVl1MFI0dllOc3c2Y1VTSEVYQmFnZHM0Qm94ZFV3M21PQnMyTkd5M2tzWUlKRURUSFlyWUFSakJwcTlYbmE5NFFlbERpLVZB?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals (IRWD) price target increased by 28.97% to 7.04", "summary": "This article reports that the price target for Ironwood Pharmaceuticals (IRWD) has been increased by 28.97%, bringing it to $7.04. The content provided is minimal, offering only this specific financial update without further details or analysis.", "url": "https://www.msn.com/en-us/money/topstocks/ironwood-pharmaceuticals-irwd-price-target-increased-by-28-97-to-7-04/ar-AA21UFr8?ocid=finance-verthp-feeds", "source_name": "MSN", "published_at": "2026-05-05T05:39:06", "published_display": "05 May 2026 05:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOZ3VWYklhSU5ycTZzaF80Z0ExamNYOWdEdzQ5OVMwSko4UzdKM3pQMWZGTlR6QXJYMlJGUEFkbHhnOUJDNGpaRkZFRUZuMHZ3QVVjaktWeng4OWRVYnU5MWxzQnJNUXFwTF9mcVdwUEMxMFl4ZHBBY0hoaTFudm9GQTRQM3RydVlhVnFTTUVyem1VcnFkZWx4bDBhSlVEM0owOWJJQXRZMGNTZW9DUElyN3NDZWp5OTRoTFh1MzlFMA?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood (NASDAQ: IRWD) seeks 10M more equity plan shares in 2026 proxy", "summary": "Ironwood Pharmaceuticals is proposing an amendment to its Amended and Restated 2019 Equity Incentive Plan to add 10,000,000 shares for equity awards, seeking stockholder approval at its 2026 annual meeting on June 16, 2026. The company emphasizes the necessity of this increase to", "url": "https://www.stocktitan.net/sec-filings/IRWD/def-14a-ironwood-pharmaceuticals-inc-definitive-proxy-statement-4b2a5c9cf462.html", "source_name": "Stock Titan", "published_at": "2026-04-28T23:09:06", "published_display": "28 Apr 2026 23:09", "sentiment": "positive", "sentiment_pct": 61, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Book value per share of Ironwood Pharmaceuticals, Inc. Class A \u2013 SWB:I76", "summary": "The article focuses on the book value per share of Ironwood Pharmaceuticals, Inc. Class A (SWB:I76), traded on the Stuttgart Stock Exchange. It provides financial data and a general overview of the company's financials for various periods, without delving into specific numbers in", "url": "https://www.tradingview.com/symbols/SWB-I76/financials-statistics-and-ratios/book-value-per-share/", "source_name": "TradingView", "published_at": "2026-04-28T07:39:27", "published_display": "28 Apr 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bank of America (NASDAQ: IRWD) reports 6.1% stake in Ironwood Pharmaceuticals", "summary": "Bank of America Corporation has disclosed a 6.1% beneficial ownership stake in Ironwood Pharmaceuticals (NASDAQ: IRWD), totaling 9,962,355 Class A Common Stock shares. This information comes from a Schedule 13G/A filing, referencing 163,058,316 outstanding shares as of January 31", "url": "https://www.stocktitan.net/sec-filings/IRWD/schedule-13g-a-ironwood-pharmaceuticals-inc-amended-passive-investmen-4693d838cccb.html", "source_name": "Stock Titan", "published_at": "2026-04-27T17:10:34", "published_display": "27 Apr 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Vanguard Group (NASDAQ: IRWD) reports zero beneficial ownership after realignment", "summary": "The Vanguard Group filed an amendment to its Schedule 13G/A report, declaring zero beneficial ownership of Ironwood Pharmaceuticals Inc. common stock. This change is due to an internal realignment effective January 12, 2026, where certain Vanguard subsidiaries will now report the", "url": "https://www.stocktitan.net/sec-filings/IRWD/schedule-13g-a-ironwood-pharmaceuticals-inc-amended-passive-investmen-9e7e76d1fbbc.html", "source_name": "Stock Titan", "published_at": "2026-03-29T03:39:53", "published_display": "29 Mar 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Ironwood (IRWD) Down 13.9% Since Last Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNNVI1eEMyOWhDdnNCS21TT0p5MjFNTW5MOEtOdG0yOGlZTVdVQTE1NVBxR21BRjh5elFscHJuTlNXR3FXeDZDQjA0NHBnTV9aTkxKYkZjOTZyWVBfVmRuYVVQWUV0cjlFcnNicy1ZcnEzRDY0R2NzREktUFlFVzU0bTFTRnNLbXZkV0VORDQwdHBPU3No?oc=5", "source_name": "Market source", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarissa Capital (IRWD) cuts Ironwood stake with 6.7M-share sale, keeps 5.8%", "summary": "Sarissa Capital Management LP and Alexander J. Denner have reduced their stake in Ironwood Pharmaceuticals (IRWD) through the sale of 6.7 million shares on March 17, 2026, for over $20.5 million. Despite the significant sale, Sarissa Capital still beneficially owns 5.6% of Ironwo", "url": "https://www.stocktitan.net/sec-filings/IRWD/schedule-13d-a-ironwood-pharmaceuticals-inc-amended-major-shareholder-56edba5b60da.html", "source_name": "Stock Titan", "published_at": "2026-03-19T22:40:33", "published_display": "19 Mar 2026 22:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals director Denner sells $20.5m in shares", "summary": "Ironwood Pharmaceuticals director Alexander J. Denner sold $20.5 million worth of Class A Common Stock on March 17, 2026, amidst recent stock volatility. Despite this insider sale, InvestingPro analysis suggests the stock is undervalued, and analysts like Jefferies and Citizens h", "url": "https://m.uk.investing.com/news/insider-trading-news/ironwood-pharmaceuticals-director-denner-sells-205m-in-shares-93CH-4564712?ampMode=1", "source_name": "Investing.com UK", "published_at": "2026-03-18T18:39:28", "published_display": "18 Mar 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals director Denner sells $20.5m in shares By Investing.com", "summary": "Ironwood Pharmaceuticals director Alexander J. Denner sold $20.5 million worth of Class A Common Stock on March 17, 2026, amidst recent stock volatility but a significant yearly gain. Despite the insider sale, InvestingPro analysis indicates the stock is undervalued, and several ", "url": "https://za.investing.com/news/insider-trading-news/ironwood-pharmaceuticals-director-denner-sells-205m-in-shares-93CH-4170170", "source_name": "Investing.com South Africa", "published_at": "2026-03-18T07:39:46", "published_display": "18 Mar 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarissa funds trim Ironwood (NASDAQ: IRWD) stake with 6.7M-share sale", "summary": "Investment vehicles advised by Sarissa Capital Management LP, associated with director Alexander J. Denner, sold off 6.7 million shares of Ironwood Pharmaceuticals (NASDAQ: IRWD) Class A Common Stock on March 17, 2026, at prices between $3.05 and $3.31 per share. This major sale ", "url": "https://www.stocktitan.net/sec-filings/IRWD/form-4-ironwood-pharmaceuticals-inc-insider-trading-activity-58e7fb54828d.html", "source_name": "Stock Titan", "published_at": "2026-03-18T01:09:13", "published_display": "18 Mar 2026 01:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals (IRWD) CFO receives 136,612-share stock grant", "summary": "Ironwood Pharmaceuticals (IRWD) CFO Gregory S. Martini received an equity compensation grant of 136,612 shares of Class A Common Stock on March 10, 2026. This award is in the form of restricted stock units, vesting in four equal installments over approximate anniversaries of the ", "url": "https://www.stocktitan.net/sec-filings/IRWD/form-4-ironwood-pharmaceuticals-inc-insider-trading-activity-d3ec7dc276ef.html", "source_name": "Stock Titan", "published_at": "2026-03-16T08:09:33", "published_display": "16 Mar 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood (NASDAQ: IRWD) CCO granted 136,612 restricted shares as equity award", "summary": "Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) Chief Commercial Officer Tammi L. Gaskins was granted 136,612 restricted shares of Class A Common Stock as an equity award. This compensation award vests in four equal annual installments, tying the value to continued service and perf", "url": "https://www.stocktitan.net/sec-filings/IRWD/form-4-ironwood-pharmaceuticals-inc-insider-trading-activity-c7eccaf99336.html", "source_name": "Stock Titan", "published_at": "2026-03-15T10:39:34", "published_display": "15 Mar 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood (NASDAQ: IRWD) CEO receives 409,836-share restricted stock award", "summary": "Ironwood Pharmaceuticals (NASDAQ: IRWD) CEO Thomas A. McCourt was granted a restricted stock unit award of 409,836 shares of Class A Common Stock. This annual performance award, valued at $0 per share, vests in three equal installments on each approximate anniversary of the grant", "url": "https://www.stocktitan.net/sec-filings/IRWD/form-4-ironwood-pharmaceuticals-inc-insider-trading-activity-0490eea8cf0a.html", "source_name": "Stock Titan", "published_at": "2026-03-13T18:09:42", "published_display": "13 Mar 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Ironwood Pharmaceuticals Stock Skyrocket Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOY1hVMGx1dmwwaHlmTnFrR0VHT3FUbGlsMFNrZUJEcnpCaHczMVZFb1hwdk1xWkY0Z0p5SWZQeV9IX2lUSGNfVWpVbHlDblhna0hLRTdhOUR6Z0xZa1BfYXJOdGdkd2txYk9Bd3VZb3hjNDd0eV9ZRmJiTGRFaE9sbmpETm5rRUNrYUJEbDBZalJYUjR2OVY2U25jUHlLSE80d09iWDhrNURUT2F0?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals: Downgrading On Pipeline Setback And Extended Timeline For Apraglutide", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOS2JfVkMwTE5FNHJoeUJwMEFtT3lKamQ2QzdQRFRpNTFyYXNFeXZHSV9hN2ZfRDZOUk1CMkRwaUdWRVk4ODRiTUJ5eDJUbWNFSGtiUVZfNURtRXdFNHJmVEVhd2Vidk9aU2JRbkpWYWdMSlhrNlM2N0dUVUNRV2ItZU9Ec1pHSzBGdW92OU5PTU45NXYzbW9ZRGdra1Q0Sk0yeEpsVl9XelFNWVl4T1liRThRT2s4VkxHdlRFVVJleEM5ZkxqWG9n?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood vs. Bausch Health: Which GI Drug Stock is a Better Pick Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE9XaEtqYWpwalIyaUxWWUlpem9pSUJTWEo1UmtPel81VjUwaHRNMzFGVTVPQ1huQXp5dEJ0SFdJUzBwTzJjS2RYUFk3NTFUVm1WRk94REt6WG1CeURmOS1qZ0pCN3E2d3h0NW9JMXhZbF9SUmpFdWo4RHF3QWpGWDg?oc=5", "source_name": "Market source", "published_at": "2026-02-20T08:00:00+00:00", "published_display": "20 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Shares Bounce 32% But Its Business Still Trails The Industry", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-06T08:00:00+00:00", "published_display": "06 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Ironwood Pharmaceuticals (IRWD) Is Up 37.8% After New 2026 Guidance And Ferring Settlement", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-06T08:00:00+00:00", "published_display": "06 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Need To Know: Analysts Are Much More Bullish On Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Revenues", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-12T08:00:00+00:00", "published_display": "12 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxPU01qVk1jRkRUTm9kbjhnb1hReG1iSmR5UEhVY255Y1RpYVBKODBwSHltVjhaZ3NsWDFVVHdreFRCdktvb2dkMmtqd2RtelI5RUlEMWRnU3JySU9GZ194b2pkOXRCZ1BsRmo3WFBtRWZpSHRIdF9rQllLb2ZhSTUtX3FOdFdMWjY5S0tQdUkyR2duT3BFX3RSRlZ5ZTUtY2ZXVjRUQzNlVWNjSi1RQWZmVFlia1VzM05GWEJ2QmJNOWtkRnhyd2ZtYk9aeS1aRWlpdG1meDRmZkxNUzBP?oc=5", "source_name": "BioSpace", "published_at": "2025-08-07T07:00:00+00:00", "published_display": "07 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswJBVV95cUxQaVpuWmR2RmZnRGpUT3hrOVVoOHFaTjU5NnN6SFBSZjZQOGgzQjlfaGcwVERFV09iLVdnYndKRmxEVWZSS2R3dWwxSnZKdEdZR1ZNejZKNG05VzhEakZwRmJGZ0pWanQ2dXFVaHhtN21lVmZpaEY5OGZDcXFDSVZGSjE4MUJlRXl4TzF4RlM4amc0X1VvN1k0NFk2RU40dmRqQ0tQWTNhTWt4OFVFVV9wbFFSdTZ6d1BRM3NmVmNIdXM2VkJiRXM1OFpvOVp3X3IwZ0JwVHU1QjZ6bmZXenVpRko3dlNnQXVWWDQwMVpLRmFiS25ldkFfS3kxeG9iX1B2UzRVV0hMZC1BQU5Ub3ZScmxkQTdzRlE5a3k2RmViR0h2NC1BUWp3NmR0cVpSdDg1Y2RV?oc=5", "source_name": "Ironwood Pharmaceuticals", "published_at": "2025-04-25T07:00:00+00:00", "published_display": "25 Apr 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 88, "total_relevant": 57, "sentiment_summary": {"positive": 9, "negative": 3, "neutral": 45, "score": 52, "total": 57, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 17.75, "count": 31}, {"event": "earnings", "label": "Earnings", "weight": 6.6, "count": 12}, {"event": "deals", "label": "Deals and strategy", "weight": 2.75, "count": 5}, {"event": "guidance", "label": "Guidance", "weight": 1.65, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}], "positive_events": 9, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 3.54, "latest_week": "2026-06-19", "one_week_move": -3.0, "four_week_move": -9.7, "twelve_week_move": 15.7, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.493668, "market_dynamics_buy_signal": false, "relative_strength": 6.659307, "fair_value_gap": -32.8, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 50.1978, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-3.0% over one week, -9.7% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 60, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 26}, {"label": "Market source", "count": 4}, {"label": "AD HOC NEWS", "count": 4}, {"label": "simplywall.st", "count": 3}, {"label": "Business Wire", "count": 2}, {"label": "MT Newswires", "count": 2}, {"label": "FinancialContent", "count": 2}, {"label": "Seeking Alpha", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 57}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 31}, {"label": "Earnings", "count": 12}, {"label": "Deals and strategy", "count": 5}, {"label": "Guidance", "count": 3}, {"label": "Regulatory and legal", "count": 2}, {"label": "Balance sheet", "count": 2}, {"label": "Capital return", "count": 1}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "57", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-3.0% over one week, -9.7% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Ironwood Pharmaceuticals (IRWD) adds 10M shares to 2019 equity incentive plan"}], "updated_at": "2026-06-22T05:13:50.450960+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}